2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Pathogenesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Diseases, Immunology, Autoimmune Disorders, GVHD, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

2373 Trac disruption enhances bioenergetic fitness and tumor control after repeated antigen exposure in CD19 CAR T cells

Zhenyu Dai, Zeguo Zhao2, Taylor Soleil Jones3, Nadia Kaveh4, Jiayi Xie, PhD5, James W Jahng, PhD6, Sneh Patel7, Emmanuel Dwomoh8, Mirela Berisa9, Pamela S. Herrera10, Harold K. Elias, MD11, Sebastien Monette12, Julia A. Belk13, Haixia Xu14, Qianjin Guo15, Justin Annes16, Justin Cross, PhD17, Howard Chang, MD, PhD18, Marcel R.M. van den Brink Jr, M.D., Ph.D.19, Michel Sadelain, MD, PhD20, Justin Eyquem, PhD21, Melody Smith, MD,MS22
2 Columbia University Irving Medical Center, New York, New York, United States
3 Stanford University School of Medicine, Stanford, California, United States
4 Stanford University School of Medicine, Stanford, California, United States
5 Stanford University School of Medicine, Stanford, California, United States
6 Stanford School of Medicine, Stanford, California, United States, Stanford School of Medicine, Stanford, California, United States
7 Nova Southeastern University, Dania, Florida, United States, Stanford University School of Medicine, Stanford, California, United States
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States, SUNY Upstate Medical University, Liverpool, New York, United States
9 Icahn School of Medicine at Mount Sinai, New York, New York, United States, Memorial Sloan Kettering Cancer Center, New York, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States
12 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Novartis Pharma AG NBS Discovery Procurement Europe, Basel, Switzerland
13 Stanford University, Stanford, California, United States
14 Stanford University, Stanford, California, United States
15 Stanford University, Stanford, California, United States
16 Stanford University, Stanford, California, United States
17 Memorial Sloan Kettering Cancer Center, New York, New York, United States
18 Amgen Inc - SSF, South San Francisco, California, United States, Stanford University, Stanford, California, United States, Stanford University, Stanford, California, United States
19 City of Hope National Medical Center, Duarte, California, United States, Memorial Sloan Kettering Cancer Center, New York, New York, United States, Weill Cornell Medical College, New York, New York, United States
20 Columbia University Irving Medical Center, New York, New York, United States
21 Memorial Sloan Kettering Cancer Center, New York, New York, United States, University of San Francisco, San Francisco, California, United States

Introduction: Disruption of the T-cell receptor α constant (TRAC) locus is an established strategy to reduce alloreactivity in allogeneic chimeric antigen receptor (CAR) T cells, but how endogenous TCR loss affects CAR T-cell metabolism and function remains incompletely defined.

Methods: Mouse and human T cells underwent TRAC disruption or matched control processing before retroviral transduction with CD19 CARs. TRAC-disrupted products were compared with matched Mock-electroporated or safe-harbor–edited control products generated in parallel. Bioenergetic and mitochondrial phenotypes were assessed by extracellular flux analysis and flow cytometric mitochondrial profiling, while RNA sequencing, ATAC sequencing, and phosphoprotein profiling were used to define associated molecular programs. Function was assessed under repeated antigen exposure to evaluate sustained cytotoxicity; in an immunocompetent syngeneic rechallenge model to assess tumor control after rechallenge; in allogeneic hematopoietic cell transplantation (allo-HCT) models to evaluate antitumor activity together with graft-versus-host disease; and in PBMC-humanized and PBMC-free xenogeneic models to examine the influence of immune context on human CAR T-cell function. Candidate signaling pathways were interrogated using the AKT inhibitor MK-2206, the mTOR inhibitor rapamycin, the JAK1/2 inhibitor ruxolitinib, or dimethyl sulfoxide vehicle.

Results: TRAC disruption preserved CAR expression, and mouse TRAC-disrupted CAR T cells retained CD19-driven proliferation despite loss of anti-CD3 responsiveness. In mouse and human T cells, TRAC disruption increased mitochondrial mass, membrane potential, respiratory reserve, and glycolytic activity without a consistent increase in MitoSOX. Paired analyses across 8 human donors confirmed these changes in untransduced T cells, and the same pattern was observed in human CD19 CAR T-cell products. Subset-resolved studies showed that the metabolic phenotype was not explained solely by altered CD4/CD8 composition. Transcriptomic and chromatin-accessibility analyses identified enrichment of mitochondrial, oxidative-phosphorylation, glycolytic, inflammatory, and cytotoxicity-associated programs. After repeated antigen exposure in vitro, TRAC-disrupted CAR T cells showed lower exhaustion and improved tumor control. In an immunocompetent A20 rechallenge model, TRAC-disrupted CAR T cells achieved earlier and deeper tumor control. In immunocompetent allo-HCT models, TRAC disruption preserved antitumor activity while reducing alloreactivity, clinical and histopathologic graft-versus-host disease (GVHD), and mortality. Likewise, human TRAC-disrupted CD19 CAR T cells also produced improved tumor control and reduced xenogeneic GVHD in a PBMC-humanized model, whereas tumor control remained comparable in PBMC-free NSG recipients. Phosphoprotein profiling revealed increased phosphorylation of nodes associated with PI3K-AKT-mTOR, CREB, and STAT3/5 signaling. To functionally interrogate these candidate pathways, we performed pharmacologic inhibition studies. The JAK1/2 inhibitor ruxolitinib reduced mitochondrial mass and membrane potential, IFN-γ and TNF-α production, and the relative cytotoxic advantage of TRAC-disrupted CAR T cells, whereas AKT or mTOR inhibition produced less consistent effects.

Conclusions: TRAC disruption has metabolic and functional consequences beyond its established role in GVHD mitigation. It preserves CAR-mediated tumor control, enhances bioenergetic capacity, and improves function after repeated antigen pressure, supporting further development of TRAC-disrupted allogeneic CAR T-cell products.

Zhenyu Dai: No relevant conflicts of interest to declare.